Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. - Paz-Ares L; Veillon R; Majem M; Zhou C; Tang KJ; Kim SW; Richardson G; Girard N; Sanborn RE; Mansfield AS; Park K; Schuchard J; et al. (Lung cancer (Amsterdam, Netherlands), 2026)